Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Predictors for autoimmune cytopenias in pediatric allo-HSCT

Jaap Jan Boelens • 20 Aug 2020
EBMT 2020
General Antibodies Rituximab

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the predictors for autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jaap Jan Boelens

4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
4:53
The influence of the pulmonary microbiome on outcomes after alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:23
PARACHUTE trial: ATG in HCST
Jaap Jan Boelens • 1 Sep 2020

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals